Analysts Offer Insights on Healthcare Companies: Spring Bank Pharmaceuticals Inc (SBPH) and SI-Bone Inc (SIBN)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spring Bank Pharmaceuticals Inc (SBPH) and SI-Bone Inc (SIBN) with bullish sentiments.

Spring Bank Pharmaceuticals Inc (SBPH)

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Spring Bank Pharmaceuticals Inc today and set a price target of $29. The company’s shares closed on Friday at $9.91.

Piros observed:

“: We are reiterating our Overweight rating and lowering our 12 month PT to $29 from $34 on Spring Bank Pharmaceuticals (moving U.S. drug launch to 2022 from 2021). This morning, the company issued a press release and hosted a call to highlight 4Q18/2018 financial results. Spring Bank announced a late- breaker abstract has been accepted for oral presentation at the Diseases (EASL) Congress (4/12). We believe results from the CATALYST studies (primarily CATALYST 2) and ACHIEVE, along with recent FDA Draft Guidance, will aid the company in designing a Phase 3 trial.”

According to TipRanks.com, Piros ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.0% and a 41.9% success rate. Piros covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Proteostasis Therapeutics Inc, and Strongbridge Biopharma Plc.

Spring Bank Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $24.

See today’s analyst top recommended stocks >>

SI-Bone Inc (SIBN)

JMP Securities analyst David Turkaly reiterated a Buy rating on SI-Bone Inc on March 8 and set a price target of $27. The company’s shares closed on Friday at $18.80.

According to TipRanks.com, Turkaly is a 4-star analyst with an average return of 13.8% and a 59.7% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Apyx Medical Corporation, Integra Lifesciences, and Nuvectra Corporation.

SI-Bone Inc has an analyst consensus of Hold.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts